Company Atossa Genetics Inc Nasdaq
Equities
US04962H2094
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Heather Rees
DFI | Director of Finance/CFO | - | 16-12-31 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 03 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-24 |
Delly Behen
ADM | Chief Administrative Officer | - | 13-12-31 |
Eric van Zanten
IRC | Investor Relations Contact | - | 22-12-06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Stephen Galli
BRD | Director/Board Member | 77 | 11-06-30 |
Jonathan Finn
BRD | Director/Board Member | 50 | Nov. 07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,077,462 | 125,684,004 ( 98.90 %) | 1,320,046 ( 1.039 %) | 98.90 % |
Stock B | 0 | 582 | 0 | 0 |
Company contact information
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.58% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |